BioCentury | Sep 28, 2017
Preclinical News

Researchers report first Haplobank data

...with single-guide RNAs (sgRNAs) increased cell survival compared with normal cells. Under a 2012 deal, Haplogen GmbH...
...unfertilized human eggs (see BioCentury Innovations, April 14, 2016) . Mark Zipkin Austrian Academy of Sciences Columbia University Evotec AG Haplogen GmbH Hebrew...
BioCentury | Jan 18, 2017
Distillery Therapeutics

Infectious disease

...expression. In a mouse model of coxsackievirus infection, PLA2G16 knockout increased survival. Next steps by Haplogen GmbH...
...include developing PLA2G16 inhibitors. TARGET/MARKER/PATHWAY: Phospholipase A2 group XVI (PLA2G16) LICENSING STATUS: Patented; licensed to Haplogen GmbH...
BioCentury | Jul 13, 2015
Company News

Cyclenium Pharma, Haplogen deal

...with an initial focus on Haplogen’s antiviral targets. Cyclenium will contribute its QUEST Library, and Haplogen...
...and screening. The companies declined to disclose financial terms. Cyclenium Pharma Inc. , Sherbrooke, Quebec Haplogen GmbH...
BioCentury | Sep 26, 2013
Tools & Techniques

Trapping human genes

...The Research Center for Molecular Medicine of the Austrian Academy of Sciences and Haplogen GmbH have generated...
...Haplogen. Superti-Furga is CEO, scientific director and a principal investigator at CeMM and cofounder of Haplogen...
...a public-private partnership between CeMM and Haplogen and is available to the scientific community at http://clones.haplogen.org/...
BioCentury | Sep 26, 2013
Distillery Techniques

Technology: Disease models

...additional genes and using the cell lines to support target and drug discovery efforts at Haplogen GmbH...
...doi:10.1038/scibx.2013.1043 Published online Sept. 26, 2013 Patent status undisclosed; available for licensing and partnerships through Haplogen...
BioCentury | Dec 17, 2012
Emerging Company Profile

Haplogen: Mining for host factors

...which it hopes will lead to the development of anti-infectives with less potential for resistance. Haplogen...
...required for cellular entry by Ebola virus (see SciBX: Science-Business eXchange, Sept. 8, 2011) . Haplogen...
...it also excludes things that are vital to the cell," he said. Casari added that Haplogen...
BioCentury | Nov 19, 2012
Finance

Highlights of weekly biotech stock moves

...and industrial applications. Evotec AG (Xetra:EVT) lost €0.05 to €2.62 last week after partnering with Haplogen GmbH...
...molecules against an undisclosed protein to treat viral infectious diseases. The protein was identified by Haplogen...
BioCentury | Nov 19, 2012
Company News

Evotec, Haplogen deal

...Evotec and Haplogen partnered to discover and develop small molecules against an undisclosed protein to treat...
...molecules against an undisclosed protein to treat viral infectious diseases. The protein was identified by Haplogen...
...its genetic screening technology. The companies declined to disclose details. Evotec AG (Xetra:EVT), Hamburg, Germany Haplogen GmbH...
BioCentury | Nov 16, 2012
Company News

Evotec, Haplogen in discovery deal for infectious diseases

...Evotec AG (Xetra:EVT) and Haplogen GmbH (Vienna, Austria) partnered to discover and develop small molecules against an...
...molecules against an undisclosed protein to treat viral infectious diseases. The protein was identified by Haplogen...
BioCentury | Sep 8, 2011
Targets & Mechanisms

Niemann-Pick(ing) on Ebola

...platform is being developed by Haplogen GmbH , a privately held biotechnology company cofounded by Brummelkamp. Haplogen...
...Boston University School of Medicine , Boston, Mass. Brigham and Women's Hospital , Boston, Mass. Haplogen GmbH...
Items per page:
1 - 10 of 10
BioCentury | Sep 28, 2017
Preclinical News

Researchers report first Haplobank data

...with single-guide RNAs (sgRNAs) increased cell survival compared with normal cells. Under a 2012 deal, Haplogen GmbH...
...unfertilized human eggs (see BioCentury Innovations, April 14, 2016) . Mark Zipkin Austrian Academy of Sciences Columbia University Evotec AG Haplogen GmbH Hebrew...
BioCentury | Jan 18, 2017
Distillery Therapeutics

Infectious disease

...expression. In a mouse model of coxsackievirus infection, PLA2G16 knockout increased survival. Next steps by Haplogen GmbH...
...include developing PLA2G16 inhibitors. TARGET/MARKER/PATHWAY: Phospholipase A2 group XVI (PLA2G16) LICENSING STATUS: Patented; licensed to Haplogen GmbH...
BioCentury | Jul 13, 2015
Company News

Cyclenium Pharma, Haplogen deal

...with an initial focus on Haplogen’s antiviral targets. Cyclenium will contribute its QUEST Library, and Haplogen...
...and screening. The companies declined to disclose financial terms. Cyclenium Pharma Inc. , Sherbrooke, Quebec Haplogen GmbH...
BioCentury | Sep 26, 2013
Tools & Techniques

Trapping human genes

...The Research Center for Molecular Medicine of the Austrian Academy of Sciences and Haplogen GmbH have generated...
...Haplogen. Superti-Furga is CEO, scientific director and a principal investigator at CeMM and cofounder of Haplogen...
...a public-private partnership between CeMM and Haplogen and is available to the scientific community at http://clones.haplogen.org/...
BioCentury | Sep 26, 2013
Distillery Techniques

Technology: Disease models

...additional genes and using the cell lines to support target and drug discovery efforts at Haplogen GmbH...
...doi:10.1038/scibx.2013.1043 Published online Sept. 26, 2013 Patent status undisclosed; available for licensing and partnerships through Haplogen...
BioCentury | Dec 17, 2012
Emerging Company Profile

Haplogen: Mining for host factors

...which it hopes will lead to the development of anti-infectives with less potential for resistance. Haplogen...
...required for cellular entry by Ebola virus (see SciBX: Science-Business eXchange, Sept. 8, 2011) . Haplogen...
...it also excludes things that are vital to the cell," he said. Casari added that Haplogen...
BioCentury | Nov 19, 2012
Finance

Highlights of weekly biotech stock moves

...and industrial applications. Evotec AG (Xetra:EVT) lost €0.05 to €2.62 last week after partnering with Haplogen GmbH...
...molecules against an undisclosed protein to treat viral infectious diseases. The protein was identified by Haplogen...
BioCentury | Nov 19, 2012
Company News

Evotec, Haplogen deal

...Evotec and Haplogen partnered to discover and develop small molecules against an undisclosed protein to treat...
...molecules against an undisclosed protein to treat viral infectious diseases. The protein was identified by Haplogen...
...its genetic screening technology. The companies declined to disclose details. Evotec AG (Xetra:EVT), Hamburg, Germany Haplogen GmbH...
BioCentury | Nov 16, 2012
Company News

Evotec, Haplogen in discovery deal for infectious diseases

...Evotec AG (Xetra:EVT) and Haplogen GmbH (Vienna, Austria) partnered to discover and develop small molecules against an...
...molecules against an undisclosed protein to treat viral infectious diseases. The protein was identified by Haplogen...
BioCentury | Sep 8, 2011
Targets & Mechanisms

Niemann-Pick(ing) on Ebola

...platform is being developed by Haplogen GmbH , a privately held biotechnology company cofounded by Brummelkamp. Haplogen...
...Boston University School of Medicine , Boston, Mass. Brigham and Women's Hospital , Boston, Mass. Haplogen GmbH...
Items per page:
1 - 10 of 10